Home > Oncology > SABCS 2021 > HR-positive/HER2-negative Breast Cancer > Consistent overall survival benefit of ribociclib in advanced breast cancer

Consistent overall survival benefit of ribociclib in advanced breast cancer

Presented By
Prof. Lisa Carey & Dr Joyce O’Shaughnessy

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
SABCS 2021
Trial
Phase 3, MONALEESA
In 3 trials, addition of ribociclib to endocrine therapy improved overall survival in postmenopausal patients with locally advanced/metastatic hormone receptor (HR)-positive/HER2-negative breast cancer. Exploratory analyses now demonstrated consistent overall survival benefit in several subgroups of patients. Addition of the CDK4/6 inhibitor ribociclib to endocrine therapy significantly improves progression-free and overall survival in patients with locally advanced/metastatic HR-positive/HER2-negative breast cancer, as was shown in the phase 3 MONALEESA-2, -3, and -7 trials (NCT01958021, NCT02422615, NCT02278120) [1–3]. Based on data from these 3 phase 3 trials, 2...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on